Caxton Associates LLP Purchases Shares of 1,716 Amgen Inc. $AMGN

Key Points

• Caxton Associates LLP has acquired a new stake of 1,716 shares in Amgen Inc., valued at approximately $535,000, during the 1st quarter of the year.
• Amgen reported a 9.4% increase in revenue year-over-year for the most recent quarter, totaling $9.18 billion, and exceeding analysts' expectations.
• The company declared a quarterly dividend of $2.38 per share, with a yield of 3.4%, scheduled to be paid on September 12th.

Caxton Associates LLP bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,716 shares of the medical research company's stock, valued at approximately $535,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. GAMMA Investing LLC raised its holdings in Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock valued at $1,140,768,000 after acquiring an additional 3,653,205 shares during the period. Nuveen LLC bought a new stake in Amgen during the 1st quarter valued at $688,868,000. Two Sigma Advisers LP raised its holdings in Amgen by 96.9% during the 4th quarter. Two Sigma Advisers LP now owns 1,545,600 shares of the medical research company's stock valued at $402,845,000 after acquiring an additional 760,700 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Amgen during the 4th quarter valued at $193,339,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Amgen by 15.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,128,328 shares of the medical research company's stock valued at $1,336,647,000 after acquiring an additional 685,785 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Price Performance

NASDAQ:AMGN traded down $6.34 during midday trading on Friday, hitting $276.39. The company had a trading volume of 2,143,109 shares, compared to its average volume of 1,855,134. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $339.17. The stock's fifty day moving average price is $292.54 and its 200-day moving average price is $291.66. The company has a market capitalization of $148.80 billion, a PE ratio of 22.60, a P/E/G ratio of 2.46 and a beta of 0.49. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the business earned $4.97 earnings per share. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.4%. Amgen's payout ratio is 77.84%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.76% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Morgan Stanley boosted their price target on shares of Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Cantor Fitzgerald restated a "neutral" rating and set a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Citigroup boosted their price target on shares of Amgen from $305.00 to $310.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen lowered shares of Amgen from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Raymond James Financial assumed coverage on shares of Amgen in a research report on Wednesday, September 3rd. They set a "market perform" rating for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $304.43.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.